Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA versus GIMOTI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA versus GIMOTI.
CLOPRA vs GIMOTI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and a 5-HT4 receptor agonist, enhancing gastrointestinal motility and having antiemetic effects via central and peripheral actions.
GIMOTI (metoclopramide) is a dopamine D2 receptor antagonist and also sensitizes tissues to acetylcholine, enhancing gastric motility and accelerating gastric emptying.
Clopra (metoclopramide) 10 mg orally or intramuscularly 30 minutes before meals and at bedtime; maximum 30 mg/day. For intravenous administration, give 10 mg over 1-2 minutes.
10 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life 6-8 hours (prolonged in renal impairment; up to 20 hours in severe CKD)
Clinical Note
moderateMetoclopramide + Haloperidol
"The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol."
Clinical Note
moderateMetoclopramide + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Metoclopramide."
Clinical Note
moderateMetoclopramide + Cyclosporine
"Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderateTerminal elimination half-life of 4-6 hours; prolonged in renal impairment (up to 10-14 hours).
Renal (50-70% as unchanged drug and metabolites); fecal (20-30%); biliary (minor ~5%)
Primarily renal (60-70% unchanged); biliary/fecal 20-30% as metabolites.
Category C
Category C
Antiemetic/Prokinetic Agent
Prokinetic Agent
Metoclopramide + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Metoclopramide."